E8 Pharmaceuticals, LLC v. Affymetrix, Inc.

• Court: Court of Appeals for the Federal Circuit
• Decided: November 6, 2013
• Docket: 13-1046
• Status: Unpublished

Opinion

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

E8 PHARMACEUTICALS, LLC AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Plaintiffs-Appellants,

v.

AFFYMETRIX, INC. AND NAVIGENICS, INC., Defendants-Appellees. ______________________

2013-1046 ______________________

Appeal from the United States District Court for the District of Massachusetts in consolidated No. 08-CV- 11132, Judge George A. O'Toole, Jr. ______________________

Decided: November 6, 2013 ______________________

JOHN B. WYSS, Wiley Rein LLP, of Washington, DC, argued for plaintiffs-appellants. With him on the brief were JAMES H. WALLACE, JR., MARK A. PACELLA, and GREGORY R. LYONS.

PETER E. ROOT, Kaye Scholer LLP, of Palo Alto, Cali- fornia, argued for defendants-appellees. With him on the brief were MICHAEL J. MALECEK, SEAN M. BOYLE, and GARY ROSS ALLEN. 2 E8 PHARMACEUTICALS, LLC v. AFFYMETRIX, INC.

______________________

Before LOURIE, DYK, and O’MALLEY, Circuit Judges. PER CURIAM. We affirm the judgment of noninfringement in favor of Affymetrix, Inc. and Navigenics, Inc. We base our decision solely on our agreement with the district court’s construction of the phrase “randomly primed PCR-derived RCG.” We do not reach any other issues raised on appeal. AFFIRMED